Table 2.
Ongoing clinical trials employing a nanoparticle carrier for the detection or treatment of prostate cancer
| NCT number | Receptor/Target | Nanoparticle Formulation | Therapeutic Payload | Clinical Use | Estimated Completion Date |
|---|---|---|---|---|---|
| 04167969 | PSMA | NOTA-PSMAi-PEG-Cy5.5-C’ | 64Cu radiolabel | MRI/PET tracer | 11/2022 |
| 03531827 | N/Aa | cyclodextrin-PEG | Camptothecin, Enzalutamideb | Anti-tumor activity in mCRPC | 12/2021 |
| 04240639, 02680535 | N/Aa | Gold nanoshell-silica core-PEG | N/A | Photothermal ablation | 06/2023 |
| 02805894 | N/Aa | Hafnium-oxide | NBTXR3 radio-enhancer | External beam radiation therapy | 11/2022 |
| 04221828, 03077659 | N/Aa | nanoparticulate paclitaxel | paclitaxel | Anti-tumor activity in prostate cancer | 01/2022 |
| 04261777 | N/Aa | Dextran-coated superparamagnetic iron oxide | Ferumoxtran-10 | MRI detection of metastatic prostate cancer | 03/2023 |
| 04089553, 04495179 | Adenosine A2a receptor | AZD4635 | AZD4635, Oleclumabb, Durvalumabb | Anti-tumor activity in mCRPC | 12/2021 |
a
Targeting based on enhanced permeability and retention (EPR) effect;
b
Co-administered with nanoparticle therapy.